First-Line Therapy for CML-CP with Nilotinib or Dasatinib Compared to Imatinib and the Incidence of Treatment-Emergent BCR-ABL Mutations in Patients Who Received Nilotinib or Imatinib for CML-CP in the ENESTnd Trial


First-Line Therapy for CML-CP with Nilotinib or Dasatinib Compared to Imatinib and the Incidence of Treatment-Emergent BCR-ABL Mutations in Patients Who Received Nilotinib or Imatinib for CML-CP in the ENESTnd Trial
Slides from presentations at ASCO 2011 and comments from Susan M O’Brien, MD

Kantarjian H et al. Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION. Proc ASCO 2011;Abstract 6510.

Dr O'Brien is Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.